Filter Results:
(927)
Show Results For
- All HBS Web
(1,281)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,281)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Sort by
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- 10 Sep 2007
- Research & Ideas
High Note: Managing the Medici String Quartet
The panel consisted of Bob Frosch, who used to head NASA and R&D for GM; Vicki Sato, who was president of Vertex Pharmaceuticals and is now on the HBS faculty; and Peter Hanke, a conductor. These people have had a lot of experience... View Details
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
communities that traditionally use the herb. The paper cites two key examples of local communities benefiting from a firm's herbal patent. In one case, members of Indian Kani tribe received royalties for the pharmaceutical version of the... View Details
- 10 Jun 2008
- First Look
First Look: June 10, 2008
Formula’ Harvard Business School Case 808-127 Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with... View Details
Keywords: Martha Lagace
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details
- July 2013 (Revised November 2021)
- Module Note
Exploration vs. Exploitation
By: Willy Shih
This module note introduces James March's concept of exploration and exploitation, and the management challenge of balancing the allocation of resources to the two activities in the firm. The note also touches on the O'Reilly and Tushman paper on the ambidextrous... View Details
Keywords: Exploration And Exploitation; Exploitation; Research; Scientific Research; Product Commercialization; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Knowledge Acquisition; Growth and Development Strategy; Resource Allocation; Strategic Planning; Research and Development; Science-Based Business; Corporate Strategy; Knowledge Sharing; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Shih, Willy. "Exploration vs. Exploitation." Harvard Business School Module Note 614-004, July 2013. (Revised November 2021.)
- 01 May 2007
- First Look
First Look: May 1, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=207113 Strategy in the 21st Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. Harvard Business School Case 707-509 The global View Details
Keywords: Sean Silverthorne
- July 2017 (Revised July 2019)
- Supplement
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)
By: Nori Gerardo Lietz and Ricardo Andrade
The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details
Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B). Harvard Business School Supplement 218-029, July 2017. (Revised July 2019.)
- July 2016 (Revised July 2019)
- Teaching Plan
Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)
By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056). View Details
- 01 Dec 2003
- Research & Ideas
Sometimes Success Begins at Failure
In the late 1980s, scientists for New York City-based drug-maker Pfizer began testing what was then known as compound UK-92,480 for the treatment of angina. Although UK-92,480 seemed promising in the lab and in animal tests, the compound showed little benefit in... View Details
- January 1975 (Revised May 1983)
- Case
CIBA-GEIGY Corp. (B)
Keywords: Pharmaceutical Industry
Salter, Malcolm S. "CIBA-GEIGY Corp. (B)." Harvard Business School Case 375-247, January 1975. (Revised May 1983.)
- January 1992
- Teaching Note
Advanced Medical Technology Corporation TN
By: Thomas R. Piper
Teaching Note for (9-287-028). View Details
Keywords: Pharmaceutical Industry
- October 2024 (Revised October 2024)
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- 2023
- Working Paper
Evaluation and Learning in R&D Investment
By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou
We examine the role of spillover learning in shaping the value of exploratory versus incremental
R&D. Using data from drug development, we show that novel drug candidates generate more
knowledge spillovers than incremental ones. Despite being less likely to reach... View Details
Frankel, Alexander P., Joshua L. Krieger, Danielle Li, and Dimitris Papanikolaou. "Evaluation and Learning in R&D Investment." Harvard Business School Working Paper, No. 23-074, May 2023. (NBER Working Paper Series, No. 31290, May 2023.)
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R＆D Investments; Drug Development; Product Shocks; M＆A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- December 2019
- Supplement
The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Business and Stakeholder Relations; Product Launch; Ethics; Society; Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)." Harvard Business School Supplement 720-423, December 2019.
- December 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem (Abridged)
By: Willy Shih
This case describes the efforts of the Bill & Melinda Gates Foundation to lower the cost of producing vaccines to prevent polio infections. It is an abridged version of HBS Case No. 620-021 with less emphasis on comparison between traditional and the new compact... View Details
Keywords: Vaccine; Manufacturing; Barriers To Entry; Production; Cost; Technological Innovation; Market Entry and Exit; Pharmaceutical Industry
Shih, Willy. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem (Abridged)." Harvard Business School Case 620-071, December 2019.